Moderna to cut $1.1 billion in costs and launch 10 new products by 2027 as it charts post-Covid future

Core Viewpoint - Moderna plans to cut approximately $1.1 billion in expenses by 2027 while aiming for 10 new product approvals, adjusting its research and development strategy following the decline of its Covid business [1][2]. Group 1: Financial Strategy - The company aims to reduce R&D spending to a range of $3.6 billion to $3.8 billion by 2027, down from an expected $4.8 billion at the end of this year [2]. - Moderna expects 2025 revenue to be between $2.5 billion and $3.5 billion, with a compounded annual growth rate of over 25% from 2026 to 2028 as new products launch [7]. Group 2: Product Pipeline and Approvals - Moderna announced positive late-stage trial results for its vaccine against respiratory syncytial virus (RSV) in high-risk adults aged 18 to 59, with plans to file for approval this year [4]. - The company has five respiratory shots with positive phase three results and expects to submit three for approval this year, including a combination shot targeting Covid and flu [6]. - Moderna has five non-respiratory products in development across cancer, latent viruses, and rare diseases that could be approved by 2027 [6]. Group 3: Research and Development Focus - The company will pause work on some products in its pipeline and sunset others to manage R&D spending effectively [3]. - Moderna's CEO stated that the company has a drug development success rate from phase one to phase three that is "six times higher" than the rest of the biotech and pharmaceutical industry [7][8].